Clinical Trials on Barotitis in Brazil

Total 3 results

The Immunobiological Technology Institute (Bio-Manguinhos)...
GlaxoSmithKline

Completed

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

Measles | Rubella | Mumps | Varicella

Brazil
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (MMR)

Measles | Rubella | Mumps

Brazil
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)

Measles | Rubella | Mumps

Brazil

3

Subscribe